Azole

Quick links to important sections

Azole

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azole

What is Azole? (Albendazole)

Property Description
Active Ingredient Albendazole
Form Tablet, Chewable Tablet, Oral Suspension
Pharmacological Class Anthelmintic (Benzimidazole)
General Purpose Curative treatment and prophylaxis of parasitic infections
Origin Synthetic compound

Azole: A Synthetic Anthelmintic Defined

Azole is a prescription-only pharmaceutical product containing the active ingredient Albendazole, and it is formally classified as a Benzimidazole anthelmintic. This classification places it within the broad category of anti-parasitic drugs specifically engineered for the systemic management of parasitic worm infestations. The medicine's efficacy is clinically recognized for its broad therapeutic use against various helminthic pathogens, and its inclusion on the WHO Essential Medicines List is noted.

The compound's definitive classification as a Benzimidazole derivative distinguishes it from other general anti-infective agents, marking it as a dedicated agent for curative treatment. While primarily intended for Human use, the core substance is also utilized in Veterinary use, reflecting its broad antiparasitic efficacy. This systemic action allows the medicine to target and address the organisms throughout the body rather than just locally.


Composition and Available Preparations

The active component, Albendazole, is a synthetic compound that functions as a prodrug and is chemically identified as a Benzimidazole carbamate. As a single active ingredient preparation, the medicine relies entirely on the rapid metabolism of Albendazole to its active form to exert its therapeutic effects.

For oral administration, Azole is supplied in several high-level dosage forms, ensuring accessibility for different patient needs. These forms include the conventional tablet, a chewable tablet, and an oral suspension. The availability of an oral suspension is a key feature, making the medicine suitable for specific patient groups, such as children, who may have difficulty swallowing solid tablet forms, while all preparations maintain the same goal of providing a systemically effective medicine.

What side effects are possible with Azole?

Possible Side Effects and Safety Information

The officially documented safety profile for Azole (Albendazole) is structured around categories of adverse reactions and specific monitoring requirements mandated by regulatory authorities, such as the FDA and EMA.

Adverse reactions are classified by frequency and system. Those categorized as uncommon (occurring in fewer than 1 in 100 patients) may include headache, dizziness, upper gastrointestinal disorders like nausea and abdominal pain, and rash or pruritus.

System-Organ Classes and Serious Reactions

Side effects are reported across several physiological domains, including Blood and the lymphatic system disorders (e.g., leukopenia, bone marrow suppression), Hepatobiliary disorders (e.g., elevated liver enzymes), and Nervous system disorders.

The official labeling highlights the risk of serious adverse reactions, although these are rare. These include severe bone marrow suppression (e.g., agranulocytosis and pancytopenia) and severe hepatic abnormalities (e.g., hepatitis). For these reasons, regulatory safety guidelines mandate mandatory monitoring of blood cell counts and liver enzymes (transaminases) before and every two weeks during treatment cycles, with discontinuation required if significant abnormalities occur.

Population and Exposure Constraints

Safety considerations apply specifically to certain patient groups. Azole is labeled with the potential for embryo-fetal toxicity, and thus pregnancy testing is required prior to initiating therapy in females of reproductive potential. In terms of duration, hepatic enzyme elevations and bone marrow suppression are noted to be more frequently associated with prolonged, higher-dose regimens. Additionally, alopecia (hair loss) is described as reversible.

Overdose and Emergency Response

The official regulatory profile for Azole overdose focuses on the risk of severe systemic toxicity. Overdose presentations are documented as an exaggeration of known adverse effects, manifesting primarily as significant hematological abnormalities, including granulocytopenia and pancytopenia, and elevated hepatic enzymes. These severe effects on the hematopoietic and hepatic systems are classified as potentially life-threatening, as fatal outcomes have been associated with severe bone marrow suppression and acute liver failure.

This severe profile necessitates that users seek emergency medical attention and immediately contact a Poison Control Center as the mandated emergency actions. Management is entirely symptomatic and supportive, as no specific antidote is known according to the prescribing information. Treatment involves general supportive therapy for the evolving clinical syndrome, along with procedural measures to remove any unabsorbed material from the gastrointestinal tract.

Continuous clinical monitoring of blood counts and liver function tests is required due to the risk of toxicity. A specific caution in the official labeling notes that patients with pre-existing liver disease are at a substantially increased risk of experiencing these severe toxicities in an overdose situation.

Therapeutic Uses of Azole

What Azole Treats: Main Uses and Benefits

Azole medications are broadly applied across therapeutic domains where additional symptomatic support is needed to address infections caused by various types of fungi and yeasts. These agents are commonly used for conditions presenting with acute episodes, ranging from localized surface issues to more serious systemic discomfort.


Symptomatic Relief and Stability

The medicine is applied in addressing symptom clusters that may become intense or disruptive, particularly symptoms related to inflammatory or irritative states. The medicine is also relevant for easing symptoms that interfere with daily functioning. It is also commonly used to help with managing systemic infections in contexts involving heightened systemic burden.

This medicine provides support that helps ease the overall symptom burden during symptomatic periods. This treatment plays a role in managing symptoms by providing supportive relief when symptoms interfere with routine activities. It supports general well-being and may assist with maintaining functional stability.

Quick Fact: Therapeutic Domain Quick Fact: Symptom Focus
Applied in conditions involving recurrent or episodic manifestations Easing symptoms related to physical discomfort

Regulatory References

  1. NIH NCBI Bookshelf overview

Eligibility and Restrictions for Use

The eligibility for Azole (Albendazole) is strictly governed by officially documented population rules. The medicine is contraindicated for any individual with a known hypersensitivity to Albendazole or to the entire benzimidazole class of compounds.

Use is not recommended for pregnant women due to the officially documented potential for fetal harm. For females of reproductive potential, regulatory authorities recommend obtaining a negative pregnancy test before starting treatment and require the use of effective contraception during and immediately following therapy. Use during lactation is generally considered compatible for single-dose administration.

Eligibility is generally established across broad age groups, including adults and children. For pediatric use, the minimum age threshold for certain indications is often cited as five years.

Conditional use and closer monitoring are required for specific comorbidities. Patients with active liver disease or dysfunction or those with pre-existing bone marrow problems must use Azole with caution due to the documented increase in risk for serious blood complications. This conditional use requires frequent laboratory observation as defined in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Medicinal product categories with documented interactions: Anticonvulsants, Myelosuppressive Agents, CYP Substrate Medicines (e.g., Theophylline), and H2-Receptor Antagonists are cited in official documents. Specific medicines that increase the exposure of the active metabolite, Albendazole Sulfoxide, include Dexamethasone, Praziquantel, and Cimetidine. Conversely, CYP-inducing agents such as Phenytoin, Fosphenytoin, Carbamazepine, Ritonavir, and Rifampicine may decrease the active metabolite’s plasma levels by increasing its metabolism.

Interaction Classifications (High-Level)

Official Interaction Statements:

  • The co-ingestion of a fatty meal or high-fat foods is officially documented to significantly enhance the oral bioavailability of the active metabolite, with systemic exposure increasing many-fold compared to fasting conditions.
  • The substance Grapefruit Juice is also documented to increase the systemic exposure of the active metabolite due to CYP3A4 inhibition.
  • Co-administration with Myelosuppressive Agents is classified as a high-risk combination due to the potential for additive bone marrow suppression.
  • Patients with pre-existing liver disease or hepatic echinococcosis are formally noted in labeling as being at increased risk for interaction-related bone marrow suppression.

Connection to the overall interaction profile

Regulatory documents define this drug's interaction structure primarily through its susceptibility to pharmacokinetic modification and its capacity for pharmacodynamic toxicity augmentation. This profile mandates official label statements regarding co-administered CYP enzyme-altering agents and requires restrictions when combined with other substances that compromise bone marrow function. The profile is unique due to the mandatory constraint of administering the product with a fatty meal to ensure adequate systemic exposure, as detailed in the official prescribing information.

Mechanism of Action

How Azole Works

The mechanism of action for Azole (Albendazole) is centered on the selective, destructive targeting of vital structures and metabolic processes unique to the parasitic helminths. The drug's activity is primarily mediated by its main active metabolite, Albendazole Sulfoxide.

Cytoskeletal Disintegration and Cellular Collapse

The active metabolite acts as a polymerization inhibitor by binding specifically to the beta-tubulin subunit within the parasite's cells . This action prevents the assembly of cytoplasmic microtubules, initiating cellular degeneration and structural collapse, particularly within the absorptive tissues of the worm.

Nutrient Transport Blockade and Lethal Energy Deprivation

The physical destruction of the microtubule network results in the functional blockade of the parasite's transport mechanisms, which are essential for absorbing nutrients like glucose. This rapid, sustained cessation of glucose uptake and utilization leads to the depletion of the parasite's glycogen reserves and subsequent failure of ATP production, resulting in immobilization and a lethal effect due to energy starvation. This mechanistic approach involves two key points of functional disruption.

Dosage and Administration Information

How Azole is Used: Official Administration Guidelines

The usage of Azole (Albendazole) is defined by established guidelines concerning the route of intake, required dosage, and overall duration of treatment. The medicine is exclusively for oral administration and is available in conventional 200 mg tablets and chewable tablets. The key principle for systemic use involves enhancing drug exposure by administering the dose with food (preferably a fatty meal).


Official Dosing and Frequency

Azole is administered twice daily (BID), and the exact quantity is determined by the patient’s body weight for major systemic infections. Individuals weighing 60 kg or more receive a fixed dose of 400 mg per administration. For those weighing less than 60 kg, the dose is calculated based on body weight, up to a maximum total daily dose of 800 mg.


Treatment Duration and Specific Conditions

Treatment duration follows either a continuous or a cyclic pattern. For Neurocysticercosis, the course typically ranges from 8 to 30 days. For Hydatid Disease, treatment is structured into a course of one 28-day cycle, followed by a 14-day drug-free interval, which is repeated for a total of three cycles.

If a dose is missed, it should be taken as soon as the lapse is remembered; however, a double dose should not be taken to compensate. The tablets may be crushed or chewed and swallowed with water if a patient has difficulty swallowing solid forms. The use protocol also notes that no dosage adjustment is generally expected for patients with renal impairment.

Recent Clinical Evidence

Azole: Recent Clinical Evidence

Recent clinical research on azole-class antifungal agents focuses primarily on optimizing usage, managing drug resistance, and evaluating newer generation triazoles (e.g., isavuconazole, posaconazole, oteseconazole).

Challenges in Treatment

One significant focus of recent investigation is the rising incidence of antifungal resistance, particularly in common pathogens like Candida species and Aspergillus fumigatus. Studies suggest that resistance may develop through mechanisms such as overexpression of efflux pumps or mutations in the target fungal enzyme, CYP51. Ongoing research explores the necessity of antifungal stewardship programs to help mitigate this issue.

Pharmacokinetic Variability

Clinical utility is increasingly guided by the concept of therapeutic drug monitoring (TDM). Research has demonstrated that patient factors, including certain genetic polymorphisms in liver enzymes (such as CYP450), can significantly affect drug metabolism and subsequent blood levels of azoles. This variability may influence the overall response in patients. Newer formulations of some azoles are also being investigated to address challenges with bioavailability and absorption that have been observed with older oral formulations.

New Generation Agents

Newer triazole derivatives are being evaluated for their role against resistant strains and in specific patient populations. For instance, oteseconazole has been the subject of Phase 3 trials for use in recurrent vulvovaginal candidiasis. Furthermore, studies are exploring the potential of combination therapy, often pairing azoles with other antifungal classes (like echinocandins) or repurposed non-antifungal drugs, as a strategy for managing complex or multi-drug resistant fungal infections.

Key Studies & References

  1. Pain Management Medications - StatPearls [Key reference for general mechanism and comparison]
  2. Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) | ClinicalTrials.gov

Frequently Asked Questions (FAQ)

Common questions about Azole (FAQ)

Q: How quickly should I generally expect Azole to start working?

The time it takes for this medicine to achieve its full therapeutic effect can vary significantly depending on the type of parasitic infection being treated. Studies and official information indicate that the initial therapeutic effects on the parasite may be observed as early as seven days. The clinical course of treatment is determined by the specific parasitic condition.

Q: How long does Azole stay in the body after the last dose?

Once absorbed, the medicine is converted into its active form, which is then processed by the body. According to official product information, the active form has an elimination half-life of approximately 8 to 12 hours. This figure is based on the drug's half-life, which measures the rate at which the medication’s concentration reduces in the bloodstream.

Q: Is it normal to feel [general symptom e.g., slightly tired] after taking Azole?

Official documentation lists certain adverse effects, such as headache, dizziness, nausea, and abdominal pain. Fatigue or general tiredness is not typically listed among the commonly reported side effects. If unexpected or persistent discomfort occurs, consultation with a healthcare professional is recommended.

Q: Does Azole interact with common supplements like vitamin D or magnesium?

The regulatory labeling details specific interactions with prescription medications and certain foods. However, it does not specifically list common vitamins or minerals like Vitamin D or magnesium. Regulatory documents emphasize the importance of discussing all supplements, herbal products, and non-prescription medicines with a healthcare provider.

Q: What kind of studies support the use of Azole?

The basis for the medicine's approval is derived from clinical studies required by regulatory agencies. These studies demonstrated its effectiveness in treating specific parasitic infections. This includes conditions such as neurocysticercosis and cystic hydatid disease, for which the medicine is indicated.

Q: Can older adults generally use Azole based on available information?

Regulatory information notes that while specific clinical studies focused only on the elderly population have not been performed, no age-specific problems have been documented in this group to date. Monitoring by a healthcare provider may be required for older adults, as is common with many medications.

Q: Is Azole commonly known by any other trade names?

The active ingredient in this medicine is Albendazole. It is available globally under its generic name and is also known by several trade names, including Albenza and Zentel.

Q: What happens if I stop taking Azole suddenly?

Regulatory patient information advises against sudden discontinuation or failing to complete the prescribed treatment course. Discontinuation against medical advice may result in incomplete parasite clearance and a subsequent return of the infection.

Q: Does the time of day matter when taking Azole?

The administration instructions indicate that the medicine must be taken with a meal, and preferably with a fatty meal, to ensure adequate absorption. Since the drug is typically dosed twice daily, the timing of the dose is typically scheduled to coincide with food intake.

Q: Can using Azole affect the results of common medical tests?

Yes, the official labeling states that this medicine may affect the results of certain common laboratory tests. Specifically, it can influence blood cell counts and liver enzyme tests. For this reason, mandatory monitoring of these tests is part of the standard care protocol during treatment cycles.

Q: What are the symptoms of an allergic reaction to Azole?

Official patient information lists signs of a serious allergic reaction. These symptoms may include developing a rash, experiencing itching or swelling (particularly of the face, tongue, or throat), and having severe dizziness, such that if observed, immediate medical help should be sought.

Q: Are there any official warnings about taking Azole with alcohol?

Official patient safety information suggests avoiding alcohol consumption while taking this medicine. This is advised to help minimize the risk of potential liver damage, which is a key safety consideration for this medication.

Q: Is Azole habit-forming or addictive?

This medicine is formally classified as an anthelmintic and is used to treat parasitic infections. The drug is not listed as a controlled substance in the U.S. regulatory system, which is an official indication used to assess the potential for abuse or dependency.

Q: What should I do if I think I'm having a side effect from Azole?

Regulatory information advises that for any suspected side effects, especially those that are severe or serious (such as severe rash, swelling, or signs of liver problems), it is necessary to seek immediate medical help. Patients may also contact their healthcare provider for guidance or submit a report of the side effect to the FDA.

Q: What is the pregnancy safety category for Azole as per regulatory documents?

While the U.S. FDA is phasing out the letter categorization system, regulatory documents provide substantive safety information. Official information states that the drug may cause fetal harm, and regulatory documents advise that females of reproductive potential should utilize effective contraception during and immediately following therapy.

Q: What resources can I trust for factual information about Azole?

Authoritative sources for drug facts include the official FDA drug labeling, which is available via DailyMed, and patient education resources from government-affiliated bodies like the NIH. These sources should be utilized in conjunction with consultation from a pharmacist or physician for specific guidance.

Q: Is it possible for Azole to interact with herbal teas?

The official documentation contains general warnings that cover herbal products and tonics. This guidance emphasizes the need to inform a healthcare provider about all non-prescription and herbal remedies being used, as these substances can sometimes influence how the medicine works.

Q: Does Azole carry a specific 'boxed' or 'black box' warning?

This medicine does not carry a formal U.S. Boxed Warning (often called a Black Box Warning). However, regulatory documents do highlight serious risks, including the potential for severe bone marrow suppression and liver enzyme elevation, which require mandatory monitoring during treatment.

How should Azole be stored and disposed of?

Storage Requirements

Official regulatory documents require that Azole (Albendazole) tablets be stored at room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be stored away from excess heat and moisture, and it is required to keep from freezing.

For stability, the medication must be kept in the original container and the container must remain tightly closed.

Child-Safety and Disposal

All forms of the medicine must be stored out of the sight and reach of children for safety, and safety caps must be locked. The product must not be used after the expiry date printed on the packaging.

Disposal instructions mandate that Azole must not be thrown away via wastewater or household waste to prevent environmental release. Unused or expired medicine must be disposed of in accordance with local pharmaceutical waste requirements; patients should consult a pharmacist for guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azole found in:

A-Z Index: